[{"from": "human", "value": "Provide a description of this molecule. [C][C][=C][C][=Branch1][Branch1][=N][N][Ring1][Branch1][N][C][=N][N][C][=Branch2][Ring1][=Branch2][=C][Branch2][Ring1][Ring2][N][=C][Ring1][Branch1][C][=Branch1][Ring2][=C][Ring1][=Branch2][C][N][C][C][O][C][C][Ring1][=Branch1][C][C][C][=C][Branch1][#Branch2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][Cl][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable imidazopyridazine and inhibitor of Janus kinase 2 mutant V617F (JAK2V617F), with potential antineoplastic activity. Upon oral administration, gandotinib selectively and competitively inhibits the activation of JAK2V617F, which may result in the inhibition of the JAK-STAT signaling pathway and the induction of apoptosis in JAK2V617F-expressing tumor cells. JAK2V617F has a substitution of phenylalanine for valine at amino acid position 617 and plays a key role in tumor cell proliferation and survival."}]